Motor Neuron Disease (MND)

Motor neuron disease (MND) is a group of conditions that slowly damage the motor neurons. Motor neurons are special nerve cells that carry signals from your brain and spinal cord to your muscles. These signals tell muscles when to move. In MND, these nerve cells get sick and die over time. Because the nerve cells die, the muscles do not get the “move” message. Muscles then become weak, thin (wasted), stiff, and they may twitch. Everyday actions—like walking, speaking, swallowing, and breathing—can become difficult.

Motor neuron disease is a group of progressive conditions that damage the nerve cells that control voluntary muscles. These nerve cells are the upper motor neurons in the brain and the lower motor neurons in the brainstem and spinal cord. When they fail, muscles weaken, shrink, and become stiff or crampy. Over time, walking, using arms and hands, speaking, swallowing, and breathing become difficult. The most common form is amyotrophic lateral sclerosis (ALS). Other forms include primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and progressive bulbar palsy (PBP). Many people use “ALS” and “MND” interchangeably. Non-invasive ventilation (NIV) and multidisciplinary care can extend survival and maintain quality of life in many people living with ALS. PubMed+1

Two sets of motor neurons can be involved:

• Upper motor neurons (UMN): These start in the brain. When they are damaged, muscles feel stiff and tight (spastic). Reflexes become brisk, and there may be signs like the Babinski sign (big toe goes up when the sole is stroked).

• Lower motor neurons (LMN): These sit in the brainstem and the front part of the spinal cord and connect directly to muscles. When they are damaged, muscles become weak, thin, and twitchy (fasciculations). Cramps are common.

Most people with MND have a mix of both upper and lower motor neuron problems. MND usually gets worse over months to years. There is no single blood test to prove MND. Doctors make the diagnosis by clinical examination, electrical tests of nerves and muscles, brain and spine scans to rule out other causes, and sometimes genetic tests.

Other names

• Motor neurone disease (spelled with an “e” in the UK and many Commonwealth countries)

• Amyotrophic lateral sclerosis (ALS) — the most common form of MND

• Lou Gehrig’s disease — a US nickname after the famous baseball player

• Charcot disease — a historical term honoring the neurologist who described it

• Spinal and bulbar muscular atrophy (SBMA or Kennedy disease) — a genetic MND subtype

• Primary lateral sclerosis (PLS) — an upper motor neuron–predominant MND

• Progressive muscular atrophy (PMA) — a lower motor neuron–predominant MND

• Progressive bulbar palsy (PBP) — MND focused on speech and swallow muscles

Types of MND

1. Amyotrophic Lateral Sclerosis (ALS): The commonest type. It affects both upper and lower motor neurons. People notice weakness, stiffness, cramps, and muscle wasting. Speech and swallowing can be involved. Breathing muscles can weaken later on.

2. Primary Lateral Sclerosis (PLS): Mostly upper motor neuron damage. Stiffness, slow and effortful walking, balance problems, and very brisk reflexes are typical. Muscle wasting and twitching are less marked. It generally progresses more slowly than ALS.

3. Progressive Muscular Atrophy (PMA): Mostly lower motor neuron damage. Weakness, muscle wasting, and fasciculations are prominent, often starting in the hands or arms. Reflexes may be reduced rather than brisk.

4. Progressive Bulbar Palsy (PBP): Mainly affects the bulbar muscles that control speech, chewing, and swallowing. Speech becomes slurred or nasal. Choking on liquids or food can occur. Emotions may feel hard to control (laughing or crying easily).

5. Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy disease): A genetic, X-linked form that usually affects men. It causes limb and bulbar weakness, muscle cramps, tremor, and sometimes hormonal features like enlarged breast tissue due to androgen receptor changes. It typically progresses slowly.

6. Adult-onset Spinal Muscular Atrophy (SMA Type IV): A genetic form due to SMN gene problems, starting in adulthood with gradual limb weakness and muscle wasting. Progression is often slower than ALS.

OR

• ALS (classical ALS). The most common adult form. It combines upper motor neuron signs (stiffness, brisk reflexes) and lower motor neuron signs (wasting, twitching). It can start in an arm or leg (“limb-onset”) or in speech/swallow muscles (“bulbar-onset”). NINDS+1

• Primary lateral sclerosis (PLS). Mainly upper motor neuron damage. People feel stiff and slow, with tight muscles and brisk reflexes. Weakness happens later. It usually progresses more slowly than ALS. NINDS

• Progressive muscular atrophy (PMA). Mainly lower motor neuron damage. Muscles waste and twitch. Reflexes may be normal or reduced at first. Some people later develop typical ALS signs. NINDS

• Progressive bulbar palsy (PBP). Starts with slurred speech, swallowing trouble, and tongue twitching or weakness. It often spreads to limbs and breathing. NICE

• MND with frontotemporal dementia (ALS-FTD). ALS with changes in thinking and behavior. People may show poor judgment, apathy, or language problems. NICE

• Genetic MNDs (for example, Kennedy’s disease and some SMAs). These are inherited and often progress more slowly, but they still injure motor neurons and weaken muscles over time. NINDS+1

Causes and contributors

MND is multifactorial. For many people, the exact cause is unknown. Scientists have identified genetic causes and several risk factors that may contribute. Below are 20 items, described in simple terms. For some, the link is strong; for others, it is an association under study:

1. C9orf72 gene expansion: A repeat segment in this gene can expand abnormally. It is a common genetic cause of both ALS and a related condition called frontotemporal dementia (FTD). It can run in families.

2. SOD1 gene mutations: Changes in the superoxide dismutase 1 gene can damage how cells handle toxic oxygen by-products. This is a well-known inherited cause in a small portion of patients.

3. TARDBP (TDP-43) gene mutations: TDP-43 protein helps manage RNA and other cell messages. Abnormal forms can clog cells and harm motor neurons.

4. FUS gene mutations: FUS is another RNA/DNA-binding protein. Mutations can lead to faulty protein handling and damage motor neurons.

5. Other ALS-related genes (e.g., OPTN, VCP, UBQLN2, TBK1, ANG): Less common genetic changes that disturb protein clearance, cellular waste handling (autophagy), or stress responses.

6. Family history: Having a parent or sibling with MND (familial MND) raises risk. Most people, however, have sporadic disease with no known family link.

7. Age: Risk rises with age, especially between 50 and 75 years, although it can occur earlier or later.

8. Sex: Men are affected slightly more often than women in many studies, especially for limb-onset disease.

9. Cigarette smoking: Linked with a higher risk in several studies. Toxins and oxidative stress may play a role.

10. Occupational or environmental toxins: Long-term exposure to pesticides, solvents, or heavy metals like lead has been associated with higher risk in some studies.

11. Head or repeated concussive injury: Prior head injury has been linked in some research, although the strength of the link varies.

12. Military service: Some large studies find higher ALS rates in veterans. Possible reasons include intense physical exertion, toxins, or injuries, but no single cause is proven.

13. High-intensity physical activity: There are mixed findings. Very vigorous, repetitive activity might be a risk in some people, but many active people never develop MND.

14. Metabolic stress and low body mass index (BMI): Lower lifetime BMI or rapid weight loss before diagnosis has been observed in some patients, suggesting energy metabolism stress could be a factor.

15. Mitochondrial dysfunction: Mitochondria are the cell’s power plants. When they fail, neurons can be more vulnerable to damage.

16. Abnormal protein handling (proteostasis failure): When cells cannot clear misfolded proteins, clumps can form and harm motor neurons.

17. Glutamate excitotoxicity: Too much glutamate (a brain chemical) can over-excite neurons and damage them. This is one reason drugs like riluzole, which affect glutamate systems, are used.

18. Neuroinflammation and microglial activation: The brain’s immune cells can become overactive, releasing chemicals that damage neurons.

19. Possible infections (under investigation): Some viruses (for example, HTLV-1) can cause motor neuron problems, but most ALS cases are not caused by infections. Research is ongoing.

20. Cyanobacterial toxins (e.g., BMAA) — debated: Exposure to certain environmental toxins has been proposed in clusters, but evidence is mixed and not conclusive.

Important note: A single person’s disease often does not have one simple cause. It is usually a combination of genetic tendency and life exposures over time.

Symptoms

1. Muscle weakness. This is the core problem. It often starts in one hand or foot and slowly spreads. People drop objects, trip, or notice a weaker grip. NCBI

2. Muscle wasting (atrophy). As the nerve supply fades, the muscle becomes thinner and smaller over time. Clothes may feel looser over the arms or legs.

3. Muscle twitching (fasciculations). Small, brief, rippling movements under the skin. They are common in ALS but can also occur in healthy people; in ALS they come with weakness and wasting. Massachusetts General Hospital

4. Cramps. Sudden, painful muscle tightening, especially in calves, hands, or thighs.

5. Stiffness and spasticity. Tight muscles and reduced flexibility from upper motor neuron damage make movement slow and jerky.

6. Brisk reflexes and abnormal reflex signs. Tapping the tendon gives an exaggerated response; a “Babinski sign” (big toe goes up) may appear.

7. Speech changes (dysarthria). Slurred, soft, or nasal speech happens when tongue, lip, or throat muscles weaken. NICE

8. Swallowing trouble (dysphagia). Coughing with water, choking on food, or meals taking much longer. Weight loss can follow. NICE

9. Drooling (sialorrhea). Not more saliva, but less efficient swallowing, so saliva pools in the mouth.

10. Breathing difficulty. First with activity, then when lying flat (orthopnea), and later even at rest. Morning headaches and daytime sleepiness may signal weak breathing muscles. NICE

11. Fatigue and weight loss. Work takes more effort; swallowing issues, higher energy burn, and depression can reduce intake and weight. NICE

12. Emotional lability (pseudobulbar affect). Sudden laughing or crying that feels out of proportion or hard to control. Massachusetts General Hospital

13. Cognitive or behavior change. Some people develop frontotemporal dementia: apathy, poor judgment, or language problems. NICE

14. Neck weakness (“head drop”). The head feels heavy; holding it upright is tiring.

15. Foot drop and gait problems. The toes catch the ground; people stumble or need a cane or brace.

Diagnostic tests

A) Physical examination

1. Pattern of progressive motor impairment. Doctors look for weakness that spreads over time and for typical upper and lower motor neuron signs in different body regions. This pattern—documented by history and repeated exams—is central to modern “Gold Coast” diagnostic criteria. BMJ Paediatrics+1

2. Upper motor neuron signs. Brisk reflexes, spasticity, and a Babinski sign suggest the brain’s movement pathways are affected. These findings help distinguish ALS/MND from pure nerve or muscle disease. BMJ Paediatrics

3. Lower motor neuron signs. Muscle wasting, reduced tone, fasciculations, and weaker reflexes show damage to the spinal cord/brainstem motor neurons. BMJ Paediatrics

4. Bulbar exam. The clinician listens to speech, watches swallowing, and inspects the tongue for twitching or weakness; a very brisk jaw jerk also points to upper motor neuron involvement. NICE

5. Gait and posture assessment. Doctors check for foot drop, balance problems, and a stiff or high-stepping walk that reflect both weakness and spasticity.

B) Manual/bedside tests

6. MRC muscle strength grading. The examiner compares strength on both sides and grades it from 0 (no movement) to 5 (normal). A simple, standardized way to track change.

7. ALS Functional Rating Scale–Revised (ALSFRS-R). A 12-item questionnaire scored by a clinician or trained staff that tracks speech, swallow, hand use, walking, and breathing. Lower scores mean worse function; it also helps with prognosis. NICE

8. Single-breath count. The person counts out loud after a deep breath. A falling number over time hints that breathing muscles are weakening.

9. Bedside swallow screen (e.g., water swallow test). Coughing, wet voice, or multiple swallows suggest aspiration risk and the need for formal swallow studies.

10. Modified Ashworth scale for spasticity. The examiner moves a limb and scores how much the muscle resists; higher scores mean more stiffness.

C) Lab and pathological tests

11. Thyroid function (TSH ± free T4). Over- or under-active thyroid can mimic weakness or cause cramps and fatigue; it must be excluded. Massachusetts General Hospital

12. Vitamin B12 ± methylmalonic acid. Low B12 can damage the spinal cord and cause weakness and brisk reflexes; replacement helps if this is the cause. Massachusetts General Hospital

13. Creatine kinase (CK). CK may be mildly raised in ALS due to muscle breakdown; very high values point to a primary muscle disease and may prompt biopsy. Massachusetts General Hospital

14. Copper and ceruloplasmin. Low copper can produce a treatable myelopathy that mimics MND; checking levels prevents missing it. Massachusetts General Hospital

15. Serum protein electrophoresis and immunofixation. These look for abnormal proteins (paraproteins) linked to neuropathies that can resemble MND and are treated differently. Massachusetts General Hospital

16. Infection and immune screens. HIV, HTLV-1, Lyme disease, and syphilis can cause motor syndromes; testing helps rule them out. Anti-GM1 antibodies help detect multifocal motor neuropathy, a treatable ALS mimic. Massachusetts General Hospital+1

D) Electrodiagnostic tests

17. Nerve conduction studies (NCS). These measure how well motor and sensory nerves conduct signals. ALS typically shows normal sensory responses and reduced motor responses without “conduction block.” Finding a motor conduction block suggests multifocal motor neuropathy, which is treatable and not ALS. Mayo Clinic+1

18. Needle electromyography (EMG). EMG looks for active denervation (fibrillation potentials and positive sharp waves) and chronic re-innervation (large motor units and reduced recruitment). EMG strongly supports the diagnosis when clinical signs fit. Mayo Clinic+1

E) Imaging tests

19. MRI of brain and spinal cord. MRI mainly rules out other problems—like disc herniation, spinal cord compression, stroke, tumors, or multiple sclerosis—that can mimic ALS. Sometimes MRI shows subtle tract changes, but that is not required for diagnosis. Massachusetts General Hospital

20. Videofluoroscopic swallow study (modified barium swallow). An X-ray movie while swallowing different textures shows if food/liquid is going into the airway and guides safe-eating advice and therapy. (Clinics will order this if bedside signs suggest aspiration.) NICE

Non-Pharmacological Treatments (therapies & others)

Each item: description with purpose & mechanism in simple terms.

1. Multidisciplinary ALS clinic care
   Care from a team—neurologist, pulmonologist, physiatrist, nurse, PT/OT, speech therapist, dietitian, social worker—improves coordination, anticipates problems, and supports you and your family. Purpose: align treatments and reduce complications. Mechanism: regular team reviews catch issues early (nutrition, breathing, equipment) and implement proven steps quickly.

2. Education & care planning
   Early, clear information on the disease, expected changes, and choices about feeding and breathing helps people stay in control. Purpose: reduce fear and crisis decisions. Mechanism: shared decision-making tools and advance directives guide care when symptoms progress.

3. Energy conservation & activity pacing
   Breaking tasks into small steps, resting before fatigue, and using adaptive tools reduces exhaustion. Purpose: save energy for important activities. Mechanism: limits overuse of weak muscles and reduces falls.

4. Physical therapy: range-of-motion & gentle strengthening
   Daily stretching and light, non-fatiguing exercises keep joints flexible and slow contractures. Purpose: preserve comfort and function. Mechanism: maintains muscle length and joint movement without overworking weakened fibers.

5. Spasticity management (non-drug)
   Regular stretching, heat, splints, and careful positioning reduce stiffness and spasms. Purpose: ease movement and pain. Mechanism: lowers reflex over-activity in tight muscles.

6. Occupational therapy & home modification
   OT recommends hand grips, dressing aids, bathroom rails, ramps, and fatigue-saving strategies. Purpose: keep independence and safety. Mechanism: adapts tasks and environments to current strength.

7. Mobility aids & orthoses
   Ankle-foot orthoses, canes, walkers, power chairs, and transfer devices reduce falls and conserve energy. Purpose: safe movement. Mechanism: braces support weak muscles; wheeled mobility prevents overexertion.

8. Speech-language therapy (SLT)
   SLT teaches clear speech strategies, pacing, and voice banking. Purpose: keep communication effective. Mechanism: compensates for bulbar weakness and plans for future assistive tech.

9. Augmentative & alternative communication (AAC)
   Message boards, speech-generating devices, eye-gaze systems, and text-to-speech apps. Purpose: preserve voice and independence. Mechanism: bypasses weak speech muscles with technology.

10. Swallow therapy & diet texture modification
    Posture changes, swallow techniques, and thickened liquids lower choking risk. Purpose: safer eating and drinking. Mechanism: slows flow, improves airway protection.

11. Nutrition counseling & high-calorie meal planning
    Early, calorie-dense meals and snacks help maintain weight and strength. Purpose: reduce malnutrition and muscle loss. Mechanism: offsets higher energy needs from breathing and movement effort.

12. Breathing monitoring & non-invasive ventilation (NIV)
    Regular tests (FVC, MIP/MEP, SNIP) identify early breathing weakness; NIV at night supports ventilation. Purpose: improve sleep, energy, survival. Mechanism: assists weakened respiratory muscles; RCTs show survival and QoL benefits, especially without severe bulbar impairment. PubMed+1

13. Cough augmentation & airway clearance
    Manual cough assist, mechanical in-exsufflation, humidification, and suction. Purpose: clear mucus and prevent pneumonia. Mechanism: compensates for weak cough muscles.

14. Pain management (non-drug)
    Positioning, heat, massage, TENS, cushions, and low-pressure mattresses. Purpose: comfort and sleep. Mechanism: reduces pressure points and muscle spasm.

15. Sleep hygiene
    Regular schedule, head-of-bed elevation, and NIV when indicated. Purpose: better rest and daytime energy. Mechanism: supports nighttime breathing and reduces awakenings.

16. Mind-body support (CBT, mindfulness, relaxation)
    Coaching, counseling, and brief therapies reduce anxiety and mood symptoms. Purpose: sustain coping. Mechanism: builds skills to manage uncertainty and stress.

17. Social work & caregiver training
    Planning benefits, respite, and practical skills (safe transfers, equipment). Purpose: reduce burnout and hospitalizations. Mechanism: equips families to manage daily care.

18. Palliative care integration (early)
    Focus on symptom control, goals, and quality of life from the start. Purpose: better comfort and aligned care. Mechanism: continuous review and anticipatory guidance.

19. Fall-prevention program
    Home hazard checks, footwear, lighting, and supervised exercise. Purpose: fewer injuries. Mechanism: reduces risk from weakness and imbalance.

20. Feeding tube (PEG) counseling at the right time
    Discuss PEG before weight loss or severe breathing weakness to keep nutrition and meds practical. Purpose: safer hydration and calorie intake. Mechanism: direct stomach access; studies show quality-of-life and possible survival benefits, though evidence is mixed—timing matters. PMC+2Cochrane+2

---

Drug Treatments

Each includes class, typical adult dosing (always individualized), timing/use, purpose, mechanism, common side effects.

1. Riluzole (anti-glutamate; disease-modifying)
   Dose: 50 mg by mouth twice daily. When: long-term from diagnosis if eligible. Purpose: modestly prolong survival. Mechanism: reduces glutamate-mediated neuronal injury. Side effects: nausea, fatigue, liver enzyme elevation (monitor). Survival benefit supported by trials and real-world data. PMC+2New England Journal of Medicine+2

2. Edaravone (Radicava / Radicava ORS) (free-radical scavenger)
   Dose: IV 60 mg over 60 min (cycle: 14 days on/14 off; then 10 of 14 days each cycle) or oral ORS with same cycle. When: in eligible ALS patients to slow functional decline. Purpose: reduce oxidative stress injury. Side effects: contusion, gait disturbance, hypersensitivity; sulfite allergy caution (IV). FDA Accessibility Data+1

3. Tofersen (Qalsody) (antisense oligonucleotide for SOD1-ALS)
   Dose: 100 mg intrathecal—3 loading doses 14 days apart, then maintenance every 28 days. When: only for genetically confirmed SOD1-ALS under the FDA’s accelerated approval. Purpose: lower SOD1 protein. Side effects: headache, procedural risks (LP), CSF pleocytosis. FDA Accessibility Data+2Biogen Investors+2

4. Baclofen (GABA-B antispastic)
   Dose: 5 mg three times daily, increase as tolerated. When: spasticity causing stiffness or cramps. Purpose: ease movement, reduce spasms. Mechanism: reduces spinal reflex activity. Side effects: sedation, weakness, dizziness; taper slowly.

5. Tizanidine (α2-agonist antispastic)
   Dose: 2 mg at bedtime; titrate. When: spasticity limiting function/sleep. Purpose: reduce tone. Mechanism: decreases excitatory neurotransmission. Side effects: dry mouth, hypotension, sleepiness; monitor liver enzymes.

6. Dantrolene (direct muscle relaxant)
   Dose: 25–50 mg 2–4×/day. When: refractory spasticity. Purpose: reduces muscle contraction strength. Mechanism: blocks calcium release in muscle. Side effects: weakness, hepatotoxicity (labs).

7. Diazepam or clonazepam (benzodiazepines)
   Dose: low dose at night. When: spasms, anxiety, sleep issues. Purpose: relax muscles and reduce anxiety. Mechanism: GABAergic enhancement. Side effects: sedation, falls, dependence risk.

8. Gabapentin (neuropathic pain/cramp control)
   Dose: 300 mg at night, titrate to 300–600 mg three times daily. When: neuropathic pain, cramps. Purpose: symptom relief. Mechanism: modulates calcium channels. Side effects: dizziness, drowsiness.

9. Mexiletine (class IB antiarrhythmic; off-label for cramps)
   Dose: often 150 mg twice daily (individualize). When: painful cramps. Purpose: reduce cramp frequency/intensity. Mechanism: sodium-channel blockade in muscle. Side effects: GI upset, tremor, cardiac risk—cardiology review if needed.

10. Quinine derivatives (rare use)
    Note: usually avoided due to hematologic and cardiac risks; consider only if safer options fail and risks are discussed. Purpose: cramp relief. Mechanism: reduces excitability. Side effects: thrombocytopenia, arrhythmias.

11. Glycopyrrolate (anticholinergic for drooling)
    Dose: 1 mg 2–3×/day (titrate). When: sialorrhea. Purpose: less saliva. Mechanism: blocks muscarinic receptors. Side effects: dry mouth, constipation, urinary retention.

12. Scopolamine (hyoscine) transdermal patch
    Dose: 1.5 mg patch every 72 h. When: drooling. Purpose: reduce secretions. Mechanism: anticholinergic. Side effects: confusion, blurred vision, dry mouth.

13. Atropine sublingual drops
    Dose: 1–2 drops PRN. When: episodic drooling. Purpose: quick relief. Mechanism: anticholinergic. Side effects: dry mouth, tachycardia.

14. Botulinum toxin injections (salivary glands)
    Dose: unit-based, injected by specialist. When: refractory drooling. Purpose: reduce saliva for months. Mechanism: blocks acetylcholine release. Side effects: dry mouth, swallowing changes.

15. Dextromethorphan/quinidine (Nuedexta)
    Dose: 20/10 mg twice daily. When: pseudobulbar affect (sudden laughing/crying). Purpose: control emotional lability. Mechanism: sigma-1 agonism + CYP modulation. Side effects: dizziness, diarrhea, QT issues.

16. SSRIs (e.g., sertraline)
    Dose: 25–50 mg daily; titrate. When: depression/anxiety or PBA adjunct. Purpose: mood stabilization. Mechanism: serotonin reuptake inhibition. Side effects: GI upset, sexual dysfunction.

17. Mirtazapine
    Dose: 7.5–15 mg at night. When: depression with poor sleep/appetite. Purpose: mood, sleep, appetite support. Mechanism: noradrenergic/serotonergic modulation. Side effects: sedation, weight gain.

18. Opioids (e.g., morphine, low dose)
    Dose: individualized. When: severe pain or air hunger in advanced disease. Purpose: ease dyspnea and pain. Mechanism: mu-opioid receptor action. Side effects: constipation, sedation; start low, go slow.

19. Antireflux therapy (PPIs/H2 blockers)
    Dose: standard. When: reflux worsens cough/aspiration risk. Purpose: reduce acid and irritation. Mechanism: acid suppression. Side effects: headache, diarrhea.

20. Bronchodilators/antitussives (selected cases)
    Dose: individualized. When: co-existing airway disease or excessive cough. Purpose: ease breathing and comfort. Mechanism: relax airways or suppress cough. Side effects: vary by drug.

Important: Sodium phenylbutyrate/taurursodiol (AMX0035; RELYVRIO/ALBRIOZA) was withdrawn from U.S. and Canadian markets in 2024 after a negative Phase 3 trial; in 2025 FDA published the withdrawal notice. Some patients in North America continued via free-drug programs. Discuss local availability and evidence with your clinician; do not start without current guidance. Reuters+2amylyx.com+2

---

Dietary / Molecular Supplements

(Evidence ranges from supportive to limited; use to meet nutrition needs—these are not cures.)

1. High-calorie oral supplements (e.g., ready-to-drink shakes)
   Help maintain weight when chewing/swallowing is slow. Dose: between meals per dietitian plan. Function: meet higher energy needs. Mechanism: calorie-dense nutrition reduces catabolism.

2. High-protein powders or modular protein
   Add to soft foods/drinks. Dose: per label to reach protein goals. Function: preserve lean mass. Mechanism: supports muscle protein turnover.

3. Omega-3 fatty acids (fish oil)
   May support general health; ALS disease-modifying benefit unproven. Dose: often 1–2 g/day EPA+DHA. Function: anti-inflammatory lipid support. Mechanism: alters eicosanoid signaling.

4. Vitamin D
   Correct deficiency for bone and muscle health. Dose: based on level (e.g., 1000–2000 IU/day or as prescribed). Function: bone integrity, immunity. Mechanism: nuclear receptor effects.

5. Vitamin B12 (and folate if low)
   Treat deficiency that can mimic/worsen neuropathy. Dose: oral or IM per labs. Function: nerve health. Mechanism: methylation and myelin support.

6. Creatine
   Mixed evidence for strength; generally safe in normal kidneys. Dose: 3–5 g/day. Function: energy buffer for muscle. Mechanism: phosphocreatine system support.

7. Coenzyme Q10
   No proven ALS benefit, but safe at moderate doses. Dose: 100–300 mg/day. Function: mitochondrial cofactor. Mechanism: electron transport/antioxidant.

8. Alpha-lipoic acid
   Antioxidant with limited ALS data. Dose: 300–600 mg/day. Function: redox balance. Mechanism: regenerates other antioxidants.

9. HMB (β-hydroxy-β-methylbutyrate)
   Used to support muscle in other conditions. Dose: ~3 g/day. Function: reduce muscle breakdown. Mechanism: leucine metabolite signaling.

10. Curcumin or EGCG (green tea extract)
    Anti-inflammatory/antioxidant; ALS benefit unproven. Dose: per product; check interactions. Function: general wellness. Mechanism: NF-κB and oxidative pathways.

---

Immunity-Booster / Regenerative / Stem-Cell / Gene-Directed Drugs

These are not general treatments. Most are investigational or for specific subtypes. Use only within specialist care or clinical trials.

1. Tofersen (Qalsody) – antisense oligonucleotide for SOD1-ALS
   Dose: 100 mg intrathecal with loading then every 28 days. Function: lowers toxic SOD1. Mechanism: binds SOD1 mRNA to reduce protein. Status: FDA accelerated approval (biomarker-based). FDA Accessibility Data+1

2. NurOwn® (autologous MSC-NTF cells) – investigational
   Dose: intrathecal cells in cycles within trials. Function: neurotrophic support. Mechanism: mesenchymal stem cells releasing growth factors. Status: not FDA-approved; mixed results; seek trials.

3. Ibudilast (MN-166) – investigational anti-neuroinflammatory
   Dose: commonly 50–100 mg/day in studies. Function: modulates glial activation. Mechanism: PDE-4/10 and macrophage migration inhibitory factor pathways. Status: trial drug; not approved for ALS.

4. Masitinib – investigational tyrosine-kinase inhibitor
   Dose: ~4.5 mg/kg/day in trials. Function: targets microglia/mast-cell signaling. Mechanism: c-Kit, Lyn, Fyn inhibition. Status: not FDA-approved for ALS.

5. Reldesemtiv (fast skeletal muscle troponin activator) – investigational
   Dose: e.g., 150 mg twice daily in trials. Function: improve muscle contractility. Mechanism: sensitizes troponin to calcium. Status: not approved.

6. Sodium phenylbutyrate/taurursodiol (AMX0035)
   Dose/Function: mitochondrial and ER stress modulation. Status: withdrawn in U.S./Canada in 2024 after negative Phase 3; see official notices; availability elsewhere varies. Discuss current status locally before use. Reuters+1

---

Procedures / Surgeries

1. Percutaneous endoscopic gastrostomy (PEG) tube
   Procedure: camera-guided tube through the abdominal wall into the stomach. Why: maintain nutrition/hydration and medication delivery when swallowing is unsafe or slow; may improve quality of life and possibly survival when timed appropriately. PMC+1

2. Tracheostomy with invasive ventilation
   Procedure: surgical airway with ventilator support. Why: long-term breathing support when NIV is insufficient; extends life but requires intensive caregiving and careful goal discussions.

3. Intrathecal baclofen (ITB) pump
   Procedure: surgically implanted pump infusing baclofen to spinal fluid. Why: manage severe spasticity when oral meds fail or cause sedation.

4. Salivary gland procedures (e.g., duct ligation or gland excision)
   Procedure: ENT surgery to reduce saliva flow. Why: severe drooling unresponsive to meds or botulinum injections.

5. Diaphragm pacing
   Procedure: implanted electrodes to stimulate the diaphragm. Why (historical): originally considered to support breathing—but trials showed harm and reduced survival in ALS, so it is not recommended. The Lancet+1

---

Prevention / Risk-Reduction Tips

(ALS/MND cannot be fully prevented; these steps reduce complications and maintain function.)

1. Maintain weight with early nutrition support and consider PEG at the right time. PMC

2. Get vaccinated (influenza, COVID-19, pneumococcal) to reduce respiratory infections.

3. Use NIV early when advised to improve sleep, energy, and survival. PubMed

4. Practice fall-prevention at home (rails, lighting, remove loose rugs).

5. Use proper swallowing strategies and textures to reduce choking/aspiration.

6. Do daily stretching to limit contractures and pain.

7. Consider cough-assist devices to clear mucus and prevent pneumonia.

8. Avoid overheating and dehydration; plan rest breaks.

9. Manage mood and stress; seek counseling when needed.

10. Keep regular clinic follow-ups for timely adjustments in breathing, nutrition, and equipment.

---

When to See Doctors Urgently

• New or worse shortness of breath, morning headaches, or disturbed sleep (signs of nighttime hypoventilation).

• Choking, frequent coughing during meals, or unexplained weight loss.

• Falls, injuries, or sudden big changes in strength.

• Worsening drooling or chest infections.

• Persistent low mood, anxiety, or overwhelming caregiver stress.

• Any new medication side effects (e.g., jaundice on riluzole).

• If you have a family history of ALS and want genetic counseling.

• To discuss PEG or NIV timing before an emergency arises.

---

What to Eat & What to Avoid

1. Eat: soft, moist, calorie-dense foods (oatmeal with nut butter, yogurt, mashed avocado, smoothies).

2. Eat: small, frequent meals and snacks to reduce fatigue at mealtimes.

3. Eat: adequate protein (eggs, fish, dairy, beans, soft meats) to maintain muscle.

4. Eat: liberal healthy fats (olive oil, butter, cream) if weight is falling.

5. Drink: thickened liquids if advised to improve swallow safety.

6. Avoid: dry, crumbly foods (crackers, dry rice) that are hard to swallow.

7. Avoid: thin liquids (water, juice) if you aspirate—use thickeners as taught.

8. Avoid: alcohol excess; it worsens balance and can irritate the airway.

9. Avoid: extreme diets or unproven “cures.”

10. Plan: keep high-calorie, easy snacks within reach; consider delivery services to save energy.

---

Frequently Asked Questions (FAQs)

1) Is ALS the same as MND?
ALS is the most common type of motor neuron disease; many regions use “ALS” and “MND” to mean the same illness.

2) How is MND diagnosed?
By a neurologist using history, neurological exam, EMG/NCS, MRI to rule out mimics, and sometimes genetic tests. There is no single “ALS blood test.”

3) Can MND be cured?
No cure yet. A few medicines (riluzole, edaravone) and specific gene therapy (tofersen for SOD1-ALS) can modestly slow disease or change biomarkers. Supportive care significantly affects quality of life and survival. PMC+2U.S. Food and Drug Administration+2

4) Does NIV really help?
Yes. In selected people—especially without severe bulbar involvement—randomized trials show improved survival and quality of life. PubMed

5) Will a feeding tube prolong my life?
PEG reliably helps maintain nutrition and medication access and can improve comfort; survival effects vary across studies and may depend on timing. PMC+1

6) Are stem-cell therapies available?
Outside clinical trials, no proven stem-cell therapy is approved for ALS/MND. Be cautious of costly, unregulated clinics.

7) Should I take supplements?
Use supplements to meet nutrition goals or correct deficiencies (e.g., vitamin D, B12). None is proven to stop ALS progression.

8) Why is weight so important?
Weight loss is linked to faster decline. High-calorie intake helps maintain strength and lowers complication risks.

9) Can exercise help?
Gentle, non-fatiguing stretching and light activity can preserve flexibility and comfort. Avoid over-exertion.

10) What about cramps and spasticity?
Stretching helps. Medicines like baclofen, tizanidine, gabapentin, or mexiletine may reduce cramps and stiffness; dosing is individualized.

11) How do I manage drooling?
Start with posture and suction; add anticholinergics (glycopyrrolate, scopolamine), amitriptyline, or botulinum toxin injections. ENT procedures are options if these fail.

12) Is diaphragm pacing an option?
No. Randomized trials showed harm in ALS; it’s not recommended. The Lancet

13) What about AMX0035 (RELYVRIO)?
It was withdrawn from the U.S. and Canada in 2024 after a negative trial; check current local guidance. Reuters

14) Are there gene-specific treatments?
Yes—for SOD1-ALS, tofersen is available in the U.S. under accelerated approval; other gene-targeted options are in trials. FDA Accessibility Data

15) Where should I get care?
An ALS-experienced, multidisciplinary clinic offers the best, coordinated support across breathing, nutrition, therapy, and equipment.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 15, 2025.